Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Plus Therapeutics (PSTV) Total Non-Current Liabilities (2018 - 2025)

Plus Therapeutics has reported Total Non-Current Liabilities over the past 11 years, most recently at $7.3 million for Q2 2025.

Quarterly Total Non-Current Liabilities changed N/A to $7.3 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Jun 2025, changed N/A year-over-year, with the annual reading at $11.1 million for FY2021, 22.91% up from the prior year.
Total Non-Current Liabilities was $7.3 million for Q2 2025 at Plus Therapeutics, down from $10.6 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $11.1 million in Q4 2021 and troughed at $7.3 million in Q2 2025.